Myeloid Therapeutics has successfully raised $73 million in a financing round led by Hatteras Investment Partners. New investors ARCH Venture Partners and Moore Strategic Ventures participated, along with existing investors Newpath Partners, 8VC, and Alexandria Venture Investments. The funds will be used to advance the clinical development of Myeloid’s lead cell therapy program, MT-101, for T cell lymphoma, as well as to accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, for TROP2-expressing tumors. The company aims to leverage the convergence of immunology and RNA science to address the unmet needs of cancer patients.
Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from new investors ARCH Venture Partners and Moore Strategic Ventures. All existing investors, including Newpath Partners, 8VC and Alexandria Venture Investments, also participated.
“Myeloid continues to make significant progress across all aspects of our business. We are pioneering the convergence of immunology and RNA science to build a clinical-stage portfolio of products, starting with the significant unmet needs of cancer patients,” said Daniel Getts, Ph.D., Chief Executive Officer of Myeloid. “We are pleased that such high-quality investors have joined with us to accelerate this effort.”
Proceeds from the financing will support the continued clinical development of MT-101, Myeloid’s lead cell therapy program in Phase 1/2 for T cell lymphoma, and will accelerate the development of MT-302, a first-in-class TROP2-FcA mRNA-LNP product, into a Phase 1/2 study for TROP2-expressing tumors. Additional in vivo programming candidates are also advancing to the clinic.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Clay B. Thorp, General Partner at Hatteras, added, “Hatteras focuses on investments in cutting-edge companies that are disrupting the status quo and accelerating the pace of innovation. We are highly encouraged by the innovation, execution and clinical development progress demonstrated by Myeloid. We are proud to support this field-leading Company through its next phase of growth and are optimistic that these approaches will drive a meaningful clinical outcome for patients.”
Source: BioSpace